-+ 0.00%
-+ 0.00%
-+ 0.00%

Stifel Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $48

Benzinga·12/19/2025 14:28:09
語音播報
Stifel analyst Annabel Samimy maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and lowers the price target from $55 to $48.